Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €7.99 EUR
Change Today +0.01 / 0.13%
Volume 361.0
ALMED On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
As of 9:07 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

medicrea international (ALMED) Snapshot

Open
€7.98
Previous Close
€7.98
Day High
€7.99
Day Low
€7.98
52 Week High
06/6/14 - €10.60
52 Week Low
05/5/15 - €7.50
Market Cap
67.9M
Average Volume 10 Days
3.2K
EPS TTM
€-0.12
Shares Outstanding
8.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICREA INTERNATIONAL (ALMED)

Related News

No related news articles were found.

medicrea international (ALMED) Related Businessweek News

No Related Businessweek News Found

medicrea international (ALMED) Details

Medicrea manufactures and distributes implants in France. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracic fixation use to de-rotate and correct spinal deformities, such as scoliosis; and PASS ANT, a polyaxial low profile thoraco-lumbar system for anterior approach. The company also provides a range of implants for the cervical spine, including C-JAWS, an anterior cervical spinal fixation system; IMPIX C, a sterile PEEK Optima cervical inter body device; Impix C+, a sterile PEEK Optima cervical inter body device that is prefilled with bone substitutes; and MANTA, a sterile PEEK Optima cervical inter body device, which is preassembled on holder and delivers with disposable instrumentation kit. Its implants for cervical spine also include MANTA +, a sterile PEEK Optima cervical inter body device, which is prefilled with bone substitutes, as well as preassembled on disposable holder and delivered with disposable instrumentation kit; GRANVIA C, a MRI compatible ceramic cervical disc; and LaminoJAWS, a cervical laminoplasty implant with a posterior approach. In addition, the company offers implants for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK Optima lumbar inter body device for posterior approach; IMPIX ALIF, a sterile PEEK Optima lumbar inter body device for anterior approach; and OSMOSYS, a macro porous bone substitute. Its implants are designed to treat scoliosis, degenerative deformation, trauma, and tumors; and are used in various traditional and advanced surgical techniques, such as minimally-invasive surgery. The company was founded in 1990 and is based in Lyon, France.

140 Employees
Last Reported Date: 04/9/15
Founded in 1990

medicrea international (ALMED) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medicrea international (ALMED) Key Developments

The MEDICREA Group Announces U.S. Launch of New Generation LigaPASS® Band System for Spinal Posterior Fixation

The MEDICREA Group announced the U.S. launch of LigaPASS® 2.0 generation, MEDICREA's band connector technology for posterior thoraco-lumbar fixation. The next-generation technology features numerous improvements and is now cleared for use in adolescent idiopathic and neuromuscular scoliosis patients 10 years of age and older in addition to adults. With over 5,000 LigaPASS® systems implanted worldwide in the past two years, MEDICREA's proprietary technology provides surgeons with a safe and efficient alternative solution to screws and hooks that allows translation and derotation of vertebral bodies. The new generation system features an extended range of connectors, a band with a narrower malleable tip to allow for safer passage underneath the lamina and a dual-band option, which allows surgeons to pass two bands underneath the lamina at once, saving considerable time during neuromuscular cases.

The MEDICREA Group Announces Audited Earnings Results for the Year 2014

The MEDICREA group announced audited earnings results for the year 2014. For the year, the company reported sales were EUR 24.2 million compared to EUR 22.9 million for the same period in last year. Operating income before amortization and provision (EBITDA) was EUR 2.5 million compared to EUR 4.4 million for the same period in last year. Loss before tax was EUR 0.7 million compared to income before tax of EUR 1.3 million for the same period in last year. Net loss was EUR 1.0 million compared to net profit of EUR 0.4 million for the same period in last year.

Medicrea Group Announces Annual Sales Results for 2014

The MEDICREA Group announced annual sales results for 2014. For the period the company reported total sales of EUR 24.2 million compared to EUR 22.9 million a year ago. In 2014, for the first half of the year, the buoyant growth recorded on the American and French markets was offset by the temporary import problems encountered in Brazil. Over the second half, revenue increased by 12% compared with the same period of 2013. The Group sales exceeding EUR 6.5 million over the fourth quarter of the year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALMED:FP €7.99 EUR +0.01

ALMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALMED.
View Industry Companies
 

Industry Analysis

ALMED

Industry Average

Valuation ALMED Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICREA INTERNATIONAL, please visit www.medicrea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.